Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	7.10T +108.6%
Revenue (ttm)	1.47T -6.4%
Net Income	116.48B -27.5%
EPS	9,186.55 -27.5%
Shares Out	12.68M
PE Ratio	60.96
Forward PE	39.28
Dividend	1,250.00 (0.22%)
Ex-Dividend Date	Mar 30, 2026

Volume	126,009
Average Volume	105,281
Open	530,000
Previous Close	519,000
Day's Range	530,000 - 565,000
52-Week Range	214,500 - 647,000
Beta	0.55
RSI	56.38
Earnings Date	Apr 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.